Cochlear

You’ll rarely get a good opportunity to buy a business of Cochlear’s quality without some sort of crisis, and this morning’s profit warning, which has sent the share price down 17% today, is just such a crisis. In this morning’s update we said we’d upgrade if the price fell ‘well below’ $55, and here we are at about $53, only 17% above the low of $45.75 reached in late 2011 when the company announced a recall of its Nucleus 5 implants. The company undoubtedly faces challenges, including losing market share with its Nucleus 5 implant still off the market...

You’ll rarely get a good opportunity to buy a business of Cochlear’s quality without some sort of crisis, and this morning’s profit warning, which has sent the share price down 17% today, is just such a crisis. In this morning’s update we said we’d upgrade if the price fell ‘well below’ $55, and here we are at about $53, only 17% above the low of $45.75 reached in late 2011 when the company announced a recall of its Nucleus 5 implants.

{{content.question}}

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa
Mastercard

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device


Register as a new member

(using a different email)

Related Articles